Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?

Alcon’s ALC platform expansion through investments, acquisitions and partnerships is likely to support growth in the upcoming quarters. The company’s new platforms and lenses are also gaining adoption. However, challenging tariff conditions and intense competition may adversely impact its operations.

In the past year, this Zacks Rank #3 (Hold) stock has dipped 8.4% compared with the industry’s 2.5% decline. The S&P 500 composite has risen 20.3% in the same time frame.

The renowned pharmaceutical and medical device manufacturer has a market capitalization of $32.77 billion. ALC’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 4.2%.

Let’s delve deeper.

Upsides for ALC

Business Development Activities: Alcon continues to expand its platform across surgery, diagnostics and ocular health by adding external technologies. Its 2025 majority investment in Aurion Biotech added AURN001 to its pipeline, while the acquisitions of LumiThera and Cylite brought Valeda for early and intermediate dry age-related macular degeneration and Hyperparallel Optical Coherence Tomography technology for cataract diagnostics, respectively.

In the second quarter of 2026, Valeda adoption increased as the installed base and utilization rose, and management said the platform could generate $100 million to $150 million of sales over a three-to-five-year period. Alcon also announced a collaboration with RxSight to combine advanced optics and lens architecture with an adjustability platform. These additions extend the company’s development options beyond internal R&D while supporting participation across multiple eye-care categories.

New Products Strengthen Growth Prospects: Alcon’s growth strategy remains tied to a broad launch cadence across equipment, IOLs, dry eye and contact lenses. Unity VCS and Unity CS continue to lead the current equipment cycle, while the company made its first sale of the Unity M microscope in the second quarter of 2026. 

PanOptix Pro is now rolling out internationally following rapid adoption in the United States while TruPlus has entered a KOL launch in the country after receiving CE Mark approval in Europe. Vivity Pro has been submitted in both the United States and Europe, with management expecting a key opinion leader (KOL) launch late in 2026 or early 2027. Unity DX is expected to enter pilot use later in 2026, with revenues anticipated around mid-2027. Tryptyr, Valeda, PanOptix Pro in Europe and Unity CS are expected to contribute more in the second half. 

Image Source: Zacks Investment Research

What Ails ALC Stock?

Trade and Demand Risks Persist: Alcon remains exposed to tariff changes and uneven procedure trends that can raise costs and reduce operating leverage. In the second quarter of 2026, the company assumed U.S. import tariff rates of about 10% to 12.5% would remain in effect through year-end. 

Guidance also includes an anticipated third-quarter tariff refund of about $60 million, with roughly two-thirds expected to be reinvested in the business. Although cataract demand improved sequentially, U.S. procedure volumes remained flat, while global volumes grew only in the low single digits. These conditions leave earnings sensitive to trade policy and procedure growth, even as new product launches support sales.

Tough Competitive Landscape: Competition remains intense across both segments, particularly as Alcon defends its market share outside the United States and navigates mix transitions. 

The category also remains highly competitive, with newer entrants targeting value tiers while the market continues to shift toward daily lenses and advanced materials. These dynamics increase the company’s reliance on newer platforms to sustain growth, requiring continued investment in commercialization and physician education to preserve pricing power and market positioning over time.

ALC Stock Estimate Trend 

The Zacks Consensus Estimate for 2026 earnings per share has moved south to $3.48 in the past 30 days.

The Zacks Consensus Estimate for 2026 revenues is pegged at $11.11 billion, suggesting a 7.7% rise from the year-ago reported number.

Key Picks

Some better-ranked stocks in the broader medical space are Globus Medical GMED, Veracyte VCYT and Illumina ILMN.

Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.

GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Veracyte, sporting a Zacks Rank #1 at present, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%. 

Illumina, presently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 13% compared with the industry’s 23% growth. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 9.7%. ILMN’s shares have rallied 194.6% compared with the industry’s 24.6% growth over the past year.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research